An update of the apex study

Alessandro Corso

doi:10.4081/hmr.v2i5.380

Articles

8 June 2009

Vol. 2 No. 5: Bortezomib (Velcade®) in multiple myeloma: an update

https://doi.org/10.4081/hmr.v2i5.380

An update of the apex study

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

315

Views

1347

Downloads

Authors

Alessandro Corso

support@pagepress.org

APEX, a pivotal phase III, randomized, multicentre trial was the largest performed in relapsed multiple myeloma (MM) to date, comparing Bortezomib (Velcade®) with high dose dexamethasone (Dex). The initial results of this important study were published by Paul Richardson and colleagues in the New England Journal of Medicine (NEJM) in 2005. Since these results were published, all Velcade patients who were ongoing at the time of the NEJM publication have completed study participation (i.e. completed all cycles or discontinued the study). However, because of dexamethasone arm was halted early, the results, apart from overall survival, have only been updated for Bortezomib (Velcade®) patients.